Home » Healthcare » Pharmaceuticals » Acquired Hemophilia Treatment

Acquired Hemophilia Treatment Market By Type Of Therapeutics (Traditional Therapy, Advanced Therapy) – Growth, Share, Opportunities & Competitive Analysis, 2016 – 2023

Price: $4999

Published: | Report ID: 1124 | Report Format : PDF

According to the National Organization of Rare Disorders (NORD), acquired hemophilia is a rare autoimmune disorder characterized by bleeding in patients with a personal and family history of hemorrhages. The body produces antibodies that attack clotting factors in acquired hemophilia, most often factor VIII. Medical practitioners suggest that acquired hemophilia can potentially cause life-threatening bleeding complications in severe cases and that, in around 50% of cases, there is an identifiable underlying clinical condition; in the other 50%, no cause is known, i.e., idiopathic.

The “Global Acquired Hemophilia Treatment Market-Growth Future Prospects and Competitive Analysis, 2016–2023” offers strategic insights into the overall acquired hemophilia treatment market along with the market size and estimates for 2016 to 2023. The research study includes an in-depth examination of multiple market segments based on the therapeutic type and geographical region. The therapeutic type segment studied for analyzing the overall acquired hemophilia treatment includes two major categories: traditional and advanced therapies. The traditional therapies are further sub-categorized into steroid treatment, cytotoxic treatment, and immunomodulatory treatment. The advanced therapies are further segmented into Desmopressin, Recombinant Activated Factor VII/NovoSeven, Recombinant Activated Factor VIII/Obizur, and Activated Prothrombin Complex Concentrate (aPCC)/FEIBA.

In order to help strategic decision-makers, the report also includes competitive profiling of the leading players in the acquired hemophilia treatment market, attractive investment propositions, and market positioning of key manufacturers. Other in-depth analysis provided in the report includes:

Geographically, the global acquired hemophilia treatment market is studied for the following regional markets:

North America

  • U.S.
  • Canada

Europe

  • U.K.
  • Germany
  • The rest of Europe

Asia-Pacific

  • China
  • Japan
  • Asia Pacific as a whole

Latin America

  • Africa and the Middle East

The market size and forecast for these regional and country-level markets are presented in this study for the period 2013–2023. In addition, market growth rates for the forecast period 2016–2023 are also included in this report, considering 2015 as the base year.

This study also provides quantitative and qualitative information sets and assessment tools to better analyze the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global acquired hemophilia treatment market. In addition, tools such as key player market positioning and appealing investment propositions provide readers with insights into the competitive landscape of the global acquired hemophilia treatment market. This report concludes with a company profiles section highlighting major information about the key players engaged in the globally acquired hemophilia treatment market. In-depth competitive environment analysis and historical (2013 & 2014) market size data are also provided in the report.

So, the research study gives a complete picture of the global acquired hemophilia treatment market by estimating the market size from 2016 to 2023 and considering the above factors.

Based on the therapeutic, the acquired hemophilia treatment market is segmented into:

  • Traditional Therapies
  • Steroid Treatment
  • Cytotoxic Treatment
  • Immunomodulatory Treatment
  • Advanced Therapies
  • Desmopressin
  • Recombinant Activated Factor VII [NovoSeven]
  • Recombinant Activated Factor VIII/Obizur
  • Activated Prothrombin Complex Concentrate (aPCC)/FEIBA

According to the National Organization of Rare Disorders (NORD), acquired hemophilia is a rare autoimmune disorder characterized by bleeding that occurs in patients with a personal and family history of hemorrhages. The body produces antibodies that attack clotting factors in acquired hemophilia, most often factor VIII. Treatment strategies that are applied against acquired hemophilia are based on two major objectives. The primary objective is to achieve effective control of bleeding manifestations during acute bleeding episodes. The secondary and ultimate therapeutic objective is eliminating the inhibitor and curing the disease. The acquired hemophilia treatment market on the basis of therapeutics has been segmented into two major categories, such as traditional and advanced therapies. The traditional therapies are further sub-categorized into steroid treatment, cytotoxic treatment, and immunomodulatory treatment. The advanced therapies are further segmented into Desmopressin, Recombinant Activated Factor VII/NovoSeven, Recombinant Activated Factor VIII/Obizur, and Activated Prothrombin Complex Concentrate (aPCC)/FEIBA. The advanced therapies held the largest segment due to the introduction of novel therapies for the treatment of acquired hemophilia. According to a prospective study, FEIBA administration resulted in excellent hemostasis in 100% of patients. However, the market for traditional therapies is expected to grow at a stable rate during the forecast period due to the patent expiration of advanced therapy drugs and the introduction of breakthrough drugs currently in clinical studies.

Chapter 1 Preface 8
1.1 Report Description 8
1.1.1 Purpose of the Report 8
1.1.2 Target Audience 8
1.1.3 USP and Key Offerings 8
1.2 Research Scope 9
1.3 Research Methodology 10
1.3.1 Phase I – Secondary Research 10
1.3.2 Phase II – Primary Research 11
1.3.3 Phase III – Expert Panel Review 11
1.3.4 Assumptions 12

Chapter 2 Executive Summary 13
2.1 Acquired Hemophilia Treatment Market Portraiture 13
2.2 Acquired Hemophilia Treatment Market, by Therapeutic Type, 2015 (US$ Mn) 14
2.3 Acquired Hemophilia Treatment Market, by Geography, 2015 (Value %) 15

Chapter 3 Global Acquired Hemophilia Treatment Market Analysis 16
3.1 Global Acquired Hemophilia Treatment Market Overview 16
3.2 Prevalence of Acquired Hemophilia 17
3.3 Market Dynamics 18
3.3.1 Market Drivers 18
3.3.1.1 Rise in Geriatric Population 18
3.3.1.2 Growing Demand for Prophylaxis Strategies 19
3.3.2 Challenges 20
3.3.2.1 Availability and Accessibility Constraints 20
3.3.3 Opportunities 21
3.4 Attractive Investment Proposition 21
3.5 Competitive Analysis: Global Acquired Hemophilia Treatment Market, 2015 (Value %) 22

Chapter 4 Global Acquired Hemophilia Treatment Market Analysis, By Type of Therapeutics 24
4.1 Preface 24
4.2 Traditional Therapy 24
4.3 Advanced Therapy 27
4.3.1 Desmopressin (DDAVP) 28
4.3.2 Recombinant Activated Factor VII/NovoSeven RT 30
4.3.3 Recombinant Porcine Factor VIII/Obizur 31
4.3.4 Activated Prothrombin Complex Concentrate (aPCC)/FEIBA 32

Chapter 5 Global Acquired Hemophilia Treatment Market, By Geography 34
5.1 Preface 34
5.1.1 Global Acquired Hemophilia Treatment Market, by Geography, 2014 – 2023 34
5.2 North America (U.S. & Canada) 35
5.3 Europe (U.K., Germany & Rest of Europe) 36
5.4 Asia Pacific (China, Japan, Singapore, South Korea and Rest of APAC) 38
5.5 Latin America (Mexico, Brazil and Rest of LATAM) 39
5.6 Middle East and Africa 40

Chapter 6 Company Profiles 42
6.1 Baxalta, Inc 42
6.2 Baxter Healthcare Corporation 43
6.3 Bristol-Myers Squibb 44
6.4 Genentech, Inc. 45
6.5 Novo Nordisk A/S 46
6.6 Ferring B.V. 47
6.7 Sanofi SA 49

List of Figures

FIG. 1 Acquired Hemophilia Treatment Market, Research Methodology 10
FIG. 2 Acquired Hemophilia Treatment Market, by Type of Device, 2015 (US$ Mn) 14
FIG. 3 Acquired Hemophilia Treatment Market, by Geography, 2015 (Value %) 15
FIG. 4 Attractive Investment Proposition 22
FIG. 5 Competitive Analysis: Global Acquired Hemophilia Treatment Market, 2015 (Value %) 23
FIG. 6 Desmopressin (DDAVP) Market (US$ Mn), 2013-2023 29
FIG. 7 Recombinant Activated Factor VII/NovoSeven RT Market (US$ Mn), 2013-2023 30
FIG. 8 Recombinant Porcine Factor VII/Obizur Market (US$ Mn), 2013-2023 31
FIG. 9 Activated Prothrombin Complex Concentrate (aPCC)/FEIBA Market (US$ Mn), 2013-2023 32
FIG. 10 Latin America (Mexico, Brazil and Rest of LATAM) Acquired Hemophilia Treatment Market (US$ Mn), 2013 – 2023 39
FIG. 11 Middle East & Africa Acquired Hemophilia Treatment Market (US$ Mn), 2013 – 2023 41

List of Tables

TABLE 1 Global Acquired Hemophilia Treatment Market, By Therapeutic Type (US$ Mn), 2013 – 2023 24
TABLE 2 Global Acquired Hemophilia Treatment Market, By Traditional Therapy (US$ Mn), 2013 – 2023 25
TABLE 3 Global Acquired Hemophilia Treatment Market, By Advanced Therapy (US$ Mn), 2013 – 2023 28
TABLE 4 Global Acquired Hemophilia Treatment Market (US$ Mn), by Geography, 2013 – 2023 34
TABLE 5 North America Acquired Hemophilia Treatment Market (US$ Mn), by Country, 2013 – 2023 36
TABLE 6 Europe Acquired Hemophilia Treatment Market (US$ Mn), by Country, 2013 – 2023 37
TABLE 7 Asia-Pacific Acquired Hemophilia Treatment Market (US$ Mn), by Country, 2013 – 2023 38
TABLE 8 Baxalta, Inc: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage) 42
TABLE 9 Baxter Healthcare Corporation: Company Snapshot (Business Description; Financial Performance; Product Position/Portfolio; News Coverage) 43
TABLE 10 Bristol-Myers Squibb: Company Snapshot (Business Description; Financial Performance; Product Position/Portfolio; News Coverage) 44
TABLE 11 Genentech, Inc.: Company Snapshot (Business Description; Financial Performance; Product Position/Portfolio; News Coverage) 45
TABLE 12 Novo Nordisk A/S: Company Snapshot (Business Description; Financial Performance; Product Position/Portfolio; News Coverage) 46
TABLE 13 Ferring B.V.: Company Snapshot (Business Description; Financial Performance; Product Position/Portfolio; News Coverage) 47
TABLE 14 Sanofi SA: Company Snapshot (Business Description; Financial Performance; Product Position/Portfolio; News Coverage) 49

Frequently Asked Questions

What is the size of Acquired Hemophilia Treatment Market?

The market for Acquired Hemophilia Treatment is expected to reach US$ XX Bn in 2023.

What is the Acquired Hemophilia Treatment Market CAGR?

The Acquired Hemophilia Treatment market is expected to see significant CAGR growth over the coming years, at XX%.

What is the Forecast period considered for Acquired Hemophilia Treatment Market?

The report is forecasted from 2016-2023.

What is the base year considered for Acquired Hemophilia Treatment Market?

The base year of this report is 2015.

Who are the major players in this market?

Baxalta, Inc 42, Baxter Healthcare Corporation 43, Bristol-Myers Squibb 44, Genentech, Inc. 45, Novo Nordisk A/S 46 are some of the major players in the global market.

U.S. 503b Compounding Pharmacies Market

Published:
Report ID: 15988

Inulin Market

Published:
Report ID: 11192

Drug Discovery Market

Published:
Report ID: 38270

Neurotrophic Keratitis Treatment Market

Published:
Report ID: 33425

Japan’s Pharmacy Automation Market

Published:
Report ID: 37511

Sterile Active Pharmaceutical Ingredient Market

Published:
Report ID: 37476

Organ Preservation Solutions Market

Published:
Report ID: 37472

Middle East and Africa Veterinary Vaccines Market

Published:
Report ID: 37309

Asia Pacific Stem Cell Therapy Market

Published:
Report ID: 37280

US Active Pharmaceutical Ingredient (API) Market

Published:
Report ID: 37221

Cancer Supportive Care Market

Published:
Report ID: 1901

Middle East and Africa Radiopharmaceuticals Market

Published:
Report ID: 37164

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN